Creating a needle-free patch to deliver diabetes medication.

Who could benefit from this research

What this research studies

This research focuses on developing a needle-free microarray patch that can deliver a medication called GLP-1 receptor agonist, which is used to treat Type 2 diabetes. The approach aims to simplify the delivery method, making it easier and less intimidating for patients who may fear needles. By using a novel platform, the patch is designed to provide a consistent release of the medication, potentially improving adherence to treatment. This innovative method addresses common barriers to diabetes management, such as treatment complexity and needle anxiety.

Why it matters

Where this research is happening

• Vaxess Technologies, INC.
  Cambridge, United States Active

Researchers

• Principal investigator: Tussey, Lynda — Vaxess Technologies, INC.
• Study coordinator: Tussey, Lynda

Related research

Other NIH-funded projects on the same topics.

• Understanding how GLP-1 drugs affect energy use in brittle diabetes

  This grant looks at how GLP-1 receptor drugs change how the body handles sugar and fats, beyond lowering blood sugar or appetite, to help people with brittle diabetes.

  NIH research Harvard University D/b/a Harvard School of Public Health · Boston, United States · NIH-11599303

• GLP-1 receptor drugs and heart-brain health in diabetes and Alzheimer’s risk

  A Duke-led study will explore how GLP-1 receptor medicines and exercise affect brain and heart health in models prone to diabetes and Alzheimer’s risk.

  NIH research Duke University · Durham, United States · NIH-11536555

• GLP-1 medicines to improve heart, kidney, and metabolic health for people with HIV and type 2 diabetes

  A real-world study will look at how GLP-1 receptor agonists affect heart and kidney health and lifetime costs for people living with HIV and type 2 diabetes.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11470780

• Lifestyle plan to protect muscle and heart health for adults with obesity using GLP-1 medications

  A real-world trial tests a combined nutrition and resistance-training program versus standard care for adults starting GLP-1 weight loss drugs to preserve lean mass and cardiovascular health.

  NIH research University of Florida · Gainesville, United States · NIH-11452740

• Pre-pregnancy GLP-1 Medication Use and Stopping It: Effects on Blood Sugar and Pregnancy Outcomes

  This project looks at how using GLP-1–based weight loss medicine before pregnancy and stopping it before trying to conceive affects blood sugar and pregnancy health.

  NIH research University of Rochester · Rochester, United States · NIH-11438182

• Ways to keep weight off after stopping GLP-1 weight-loss meds

  This project tests simple strategies to help adults who have obesity keep weight off after stopping high-dose GLP-1 medicines.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11428011

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.